Cervical dysplasia associated with the use of natalizumab.
1Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, the Netherlands.
L
L
Rolfes
B
B
Lokhorst
J
J
Samijn
E
E
van Puijenbroek
D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy; D000069442:Natalizumab; D027383:Papillomaviridae; D014412:Tumor Virus Infections / Q000209:etiology*; D002578:Uterine Cervical Dysplasia / Q000209:etiology* / Q000821:virology
D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab